Student sick days are being expanded in some states to include mental health; vaped THC remains understudied due to its distinction as a controlled substance; drug company Biogen seeks approval for Alzheimer's treatment.
Amid rising rates of depression, anxiety, and suicide among adolescents, some states and school systems have begun to implement mental health days for students, which expands the definition of a sick day to stay home from school. The Washington Post reports that last year, Utah changed its definition of valid excuses for absences to include mental health issues, with Oregon enacting a similar law this past summer that allows students to take days off for mental health. These new laws, largely driven by high school student activists, are additionally being advocated for in states such as Colorado, Florida, and Washington.Although e-cigarettes were initially promoted to assist smoking cessation, the use of marijuana’s psychoactive component THC has grown in popularity, but its correlation to the epidemic of mysterious lung illnesses has caused health investigators to warn against its use, according to The New York Times. In most of the 1479 patients who have been linked to these severe lung illnesses caused by vaping, the use of THC has been reported. Due to cannabis’ distinction as a controlled substance with a high potential for abuse, scientists have been unable to study vaped THC, leaving a void in research on its attributable effect on the lungs.Drug company Biogen Incorporated announced today their intention to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease. The move comes after consulting with the FDA and after their phase 3 EMERGE study, which represented a reportedly significant reduction in clinical decline. The Associated Press reports that the announcement comes as a surprise because earlier this year, Biogen stopped 2 studies of the drug when partial results suggested a lack of efficacy. The new analysis suggests that at the highest dose, the drug, which aims to help the body clear harmful plaques from the brain, demonstrated an effective impact on patients.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More